Top

Published in:

01-11-2012 | Original paper

Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review

Authors: Megan A. Murphy, Britton Trabert, Hannah P. Yang, Yikyung Park, Louise A. Brinton, Patricia Hartge, Mark E. Sherman, Albert Hollenbeck, Nicolas Wentzensen

Published in: Cancer Causes & Control | Issue 11/2012

Abstract

Background

Chronic inflammation has been proposed as a risk factor for ovarian cancer. Some data suggest that anti-inflammatory medications may be protective against ovarian cancer; however, results have been inconsistent.

Methods

We evaluated the risk of epithelial ovarian cancer with regular use of NSAIDs prospectively in the NIH-AARP Diet and Health Study, using Cox proportional hazard models. We also examined the risk of common subtypes of epithelial ovarian cancer (serous, mucinous, endometrioid, clear cell, and other epithelial) with regular use of NSAIDs. In addition, we performed meta-analyses summarizing the risk of ovarian cancer with “regular use” of NSAIDs in previously published studies.

Results

We did not observe a significant association between regular use of NSAIDs with ovarian cancer risk in the AARP cohort (aspirin: RR 1.06, 95 % CI 0.87–1.29; non-aspirin NSAIDs: RR 0.93, 95 % CI 0.74–1.15); however, summary estimates from prospective cohort studies demonstrated that use of non-aspirin NSAIDs may reduce the risk of ovarian cancer (RR 0.88, 95 % CI 0.77–1.01). Although not significant, we found that mucinous tumors were inversely associated with non-aspirin NSAID use (RR 0.69, 95 % CI 0.23–2.10) in the AARP cohort, which was supported by the meta-analysis (RR 0.69, CI 0.50–0.94.)

Conclusion

Although results from the NIH-AARP cohort study were not statistically significant, our meta-analysis suggests that non-aspirin NSAIDs may be protective against ovarian cancer. Additional analyses, focusing on dose, duration, and frequency of NSAID use and accounting for ovarian cancer heterogeneity are necessary to further elucidate the association between NSAID use and ovarian cancer risk.

Available only for authorised users

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249. doi:10.3322/caac.20006 PubMedCrossRef

Fleming JS, Beaugie CR, Haviv I, Chenevix-Trench G, Tan OL (2006) Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 247(1–2):4–21. doi:10.1016/j.mce.2005.09.014 PubMedCrossRef

Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91(17):1459–1467PubMedCrossRef

Tzonou A, Polychronopoulou A, Hsieh CC, Rebelakos A, Karakatsani A, Trichopoulos D (1993) Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer. Int J Cancer 55(3):408–410PubMedCrossRef

Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER (1998) Over-the-counter analgesics and risk of ovarian cancer. Lancet 351(9096):104–107. doi:10.1016/S0140-6736(97)08064-1 PubMedCrossRef

Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S (2000) Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol: official journal of the European Society for Medical Oncology/ESMO 11(9):1171–1173

Rosenberg L, Palmer JR, Rao RS, Coogan PF, Strom BL, Zauber AG, Stolley PD, Shapiro S (2000) A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomark Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 9(9):933–937

Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H (2001) Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomark Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 10(8):903–906

Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE (2001) Aspirin and epithelial ovarian cancer. Prev Med 33(6):682–687. doi:10.1006/pmed.2001.0945 PubMedCrossRef

10.

Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A (2006) Analgesic drug use and risk of ovarian cancer. Epidemiology 17(1):104–107PubMedCrossRef

11.

Meier CR, Schmitz S, Jick H (2002) Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22(3):303–309PubMedCrossRef

12.

Hannibal CG, Rossing MA, Wicklund KG, Cushing-Haugen KL (2008) Analgesic drug use and risk of epithelial ovarian cancer. Am J Epidemiol 167(12):1430–1437. doi:10.1093/aje/kwn082 PubMedCrossRef

13.

Merritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122(1):170–176. doi:10.1002/ijc.23017 PubMedCrossRef

14.

Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC (2009) Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer 124(6):1409–1415. doi:10.1002/ijc.24091 PubMedCrossRef

15.

Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM (2008) Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer 98(11):1781–1783. doi:10.1038/sj.bjc.6604392 PubMedCrossRef

16.

Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE (2002) Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 13(6):535–542PubMedCrossRef

17.

Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH (2003) A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 88(5):684–688. doi:10.1038/sj.bjc.6600760 PubMedCrossRef

18.

Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA (2003) Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88(11):1687–1692. doi:10.1038/sj.bjc.6600945 PubMedCrossRef

19.

Lacey JV Jr, Sherman ME, Hartge P, Schatzkin A, Schairer C (2004) Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 108(2):281–286. doi:10.1002/ijc.11538 PubMedCrossRef

20.

Pinheiro SP, Tworoger SS, Cramer DW, Rosner BA, Hankinson SE (2009) Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol 169(11):1378–1387. doi:10.1093/aje/kwp062 PubMedCrossRef

21.

Prizment AE, Folsom AR, Anderson KE (2010) Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women’s Health Study. Cancer Epidemiol Biomark Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 19(2):435–442. doi:10.1158/1055-9965.EPI-09-0976

22.

Bonovas S, Filioussi K, Sitaras NM (2005) Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol 60(2):194–203. doi:10.1111/j.1365-2125.2005.02386.x PubMedCrossRef

23.

Bonovas S, Filioussi K, Sitaras NM (2006) Paracetamol use and risk of ovarian cancer: a meta-analysis. Br J Clin Pharmacol 62(1):113–121. doi:10.1111/j.1365-2125.2005.02526.x PubMedCrossRef

24.

Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294(1):47–55. doi:10.1001/jama.294.1.47 PubMedCrossRef

25.

Schatzkin A, Subar AF, Thompson FE, Harlan LC, Tangrea J, Hollenbeck AR, Hurwitz PE, Coyle L, Schussler N, Michaud DS, Freedman LS, Brown CC, Midthune D, Kipnis V (2001) Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol 154(12):1119–1125PubMedCrossRef

26.

Yang HP, Trabert B, Murphy MA, Sherman ME, Sampson JN, Brinton LA, Hartge P, Hollenbeck A, Park Y, Wentzensen N (2011) Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. Int J Cancer. doi:10.1002/ijc.26469

27.

Michaud DS, Midthune D, Hermansen S, Leitzmann M, Harlan LC, Kipnis V, Schatzkin A (2005) Comparison of cancer registry case ascertainment with SEER estimates and self-reporting in a subset of the NIH-AARP Diet and Health Study. J Regist Manag 32:70–75

28.

Lunn M, McNeil D (1995) Applying cox regression to competing risks. Biometrics 51(2):524–532PubMedCrossRef

29.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560. doi:10.1136/bmj.327.7414.557 PubMedCrossRef

30.

Gates MA, Rosner BA, Hecht JL, Tworoger SS (2010) Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 171(1):45–53. doi:10.1093/aje/kwp314 PubMedCrossRef

31.

Kir G, Gurbuz A, Karateke A, Kir M (2010) Clinicopathologic and immunohistochemical profile of ovarian metastases from colorectal carcinoma. World J Gastrointest Surg 2(4):109–116. doi:10.4240/wjgs.v2.i4.109 PubMedCrossRef

32.

Prat J (2005) Ovarian carcinomas, including secondary tumors: diagnostically challenging areas. Mod Pathol: an official journal of the United States and Canadian Academy of Pathology, Inc 18(Suppl 2):S99–S111. doi:10.1038/modpathol.3800312

33.

Young RH (2007) From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol 14(3):149–177. doi:10.1097/PAP.0b013e3180504abf PubMedCrossRef

34.

Modugno F, Ness RB, Chen C, Weiss NS (2005) Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomark Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 14(12):2840–2847. doi:10.1158/1055-9965.EPI-05-0493

35.

Danforth KN, Gierach GL, Brinton LA, Hollenbeck AR, Katki HA, Leitzmann MF, Schatzkin A, Lacey JV Jr (2009) Nonsteroidal anti-inflammatory drug use and endometrial cancer risk in the NIH-AARP Diet and Health Study. Cancer Prev Res (Phila) 2(5):466–472. doi:10.1158/1940-6207.CAPR-08-0239 CrossRef

36.

Bodelon C, Doherty JA, Chen C, Rossing MA, Weiss NS (2009) Use of nonsteroidal antiinflammatory drugs and risk of endometrial cancer. Am J Epidemiol 170(12):1512–1517. doi:10.1093/aje/kwp321 PubMedCrossRef

37.

Bosetti C, Bravi F, Talamini R, Montella M, Negri E, La Vecchia C (2010) Aspirin and risk of endometrial cancer: a case-control study from Italy. Eur J Cancer Prev 19(5):401–403PubMedCrossRef

38.

Moysich KB, Baker JA, Rodabaugh KJ, Villella JA (2005) Regular analgesic use and risk of endometrial cancer. Cancer Epidemiol Biomark Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 14(12):2923–2928. doi:10.1158/1055-9965.EPI-05-0457

39.

Viswanathan AN, Feskanich D, Schernhammer ES, Hankinson SE (2008) Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res 68(7):2507–2513. doi:10.1158/0008-5472.CAN-07-6257 PubMedCrossRef

40.

Fortuny J, Sima C, Bayuga S, Wilcox H, Pulick K, Faulkner S, Zauber AG, Olson SH (2009) Risk of endometrial cancer in relation to medical conditions and medication use. Cancer epidemiology, Biomarkers Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 18 (5):1448-1456. doi:10.1158/1055-9965.EPI-08-0936

41.

Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D (2007) The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146(5):365–375PubMed

42.

Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D (2007) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146(5):376–389PubMed

43.

Smalley W, Ray WA, Daugherty J, Griffin MR (1999) Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 159(2):161–166PubMedCrossRef

44.

Mahipal A, Anderson KE, Limburg PJ, Folsom AR (2006) Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women’s health study. Cancer Epidemiol Biomark Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 15(10):1785–1790. doi:10.1158/1055-9965.EPI-05-0674

45.

Sayasneh A, Tsivos D, Crawford R (2011) Endometriosis and ovarian cancer: a systematic review. ISRN Obstet Gynecol 2011:140310. doi:10.5402/2011/140310 PubMed

46.

Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13(4):385–394. doi:10.1016/S1470-2045(11)70404-1 PubMedCrossRef

47.

Wei JJ, William J, Bulun S (2011) Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects. Int J Gynecol Pathol: official journal of the International Society of Gynecological Pathologists 30(6):553–568. doi:10.1097/PGP.0b013e31821f4b85

48.

Tworoger SS, Gertig DM, Gates MA, Hecht JL, Hankinson SE (2008) Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer 112(5):1169–1177. doi:10.1002/cncr.23275 PubMedCrossRef

49.

Marchbanks PA, Wilson H, Bastos E, Cramer DW, Schildkraut JM, Peterson HB (2000) Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol 95(2):255–260PubMedCrossRef

50.

Green A, Purdie D, Bain C, Siskind V, Webb PM (2001) Cigarette smoking and risk of epithelial ovarian cancer (Australia). Cancer Causes Control 12(8):713–719PubMedCrossRef

51.

Pan SY, Ugnat AM, Mao Y, Wen SW, Johnson KC (2004) Association of cigarette smoking with the risk of ovarian cancer. Int J Cancer 111(1):124–130. doi:10.1002/ijc.20242 PubMedCrossRef

52.

Kumar V, Abbas A, Fausto N (2005) Robbins and Cotran pathologic basis of disease, 7th edn. Elsevier Saunders, Philadephia

53.

Wong HP, Yu L, Lam EK, Tai EK, Wu WK, Cho CH (2007) Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation. Toxicol Sci: an official journal of the Society of Toxicology 97(2):279–287. doi:10.1093/toxsci/kfm060

54.

Giovannucci E (2002) Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 31(4):925–943PubMedCrossRef

55.

Goodman MT, Shvetsov YB (2009) Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995–2004. Cancer Epidemiol Biomark Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 18(1):132–139. doi:10.1158/1055-9965.EPI-08-0771

Title: Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review
Authors: Megan A. Murphy
Britton Trabert
Hannah P. Yang
Yikyung Park
Louise A. Brinton
Patricia Hartge
Mark E. Sherman
Albert Hollenbeck
Nicolas Wentzensen
Publication date: 01-11-2012
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 11/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-012-0063-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2012

Regular dental visits are associated with earlier stage at diagnosis for oral and pharyngeal cancer

Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade

Estrogen in obesity-associated colon cancer: friend or foe? Protecting postmenopausal women but promoting late-stage colon cancer

Intake of omega-3 and omega-6 fatty acids and risk of ovarian cancer

Screening practices of Australian men and women categorized as “at or slightly above average risk” of colorectal cancer

Critical review and synthesis of the epidemiologic evidence on formaldehyde exposure and risk of leukemia and other lymphohematopoietic malignancies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer